Optimized dosing of spatially heterogeneous radiopharmaceutical therapy reprograms poorly immunogenic tumors to enhance response to immune checkpoint blockade
Maya E. Takashima, Zachary Danaceau, Malick Bio Idrissou, Ohyun Kwon, Tracy J. Berg, Paul A. Clark, Yujuan Wang, Wonjong Jin, Adedamola O. Adeniyi, Campbell Donnelly Haasch, Michael Antonelli, Jamey Weichert, Bryan P. Bednarz, Reinier T. Hernandez, Irene Ong, Zachary Scott Morris
This study shows that optimized spatially heterogeneous radiopharmaceutical therapy enhances immune checkpoint blockade response in poorly immunogenic tumors by promoting T cell activation and infiltration.
bioRxiv · Oct 28, 2026 · PreprintCancer Biology